Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The mechanism of action of the combination therapy, naltrexone/bupropion (NB), for obesity has not been fully described to date. Weight loss attempts rarely result in long-term success. This is likely a result of complex interactions among multiple peripheral and CNS systems that defend against weight loss, and may explain the overwhelming lack of effective obesity treatments. NB is an investigational combination therapy for obesity that was developed based on evidence that obesity involves alterations in the hypothalamic melanocortin system as well as brain reward systems that influence food craving and mood. Naltrexone and bupropion both have actions in these brain regions that may cause them to influence food intake, food craving, and other aspects of eating behavior that affect body weight. We review the individual actions of naltrexone and bupropion in brain hypothalamic and reward systems, and describe the current in vitro, in vivo, and clinical evidence for how NB influences food intake and produces weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ghrelin is a growth-hormone-releasing acylated peptide from stomach
Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999) · Nature · doi:10.1038/45230 · Cited by 8,479
What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?
Berridge, K. C., & Robinson, T. E. (1998) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00019-8 · Cited by 4,127
Haslam, D. W., & James, W. P. T. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67483-1 · Cited by 3,757
A Potential Decline in Life Expectancy in the United States in the 21st Century
Olshansky, S. J., Passaro, D. J., Hershow, R. C., Layden, J., Carnes, B. A., Brody, J., Hayflick, L., Butler, R. N., Allison, D. B., & Ludwig, D. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmsr043743 · Cited by 2,612
Central nervous system control of food intake and body weight
Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S., & Schwartz, M. W. (2006) · Nature · doi:10.1038/nature05026 · Cited by 2,503 · cited 3×
“The reward system plays a central role in regulation of eating behavior by mediating the rewarding effects of pleasurable stimuli (food, sex and drugs of abuse) and governs reward-directed behavior [26,39,60,62,63].”
BackgroundLeptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus
Cowley, M. A., Smart, J. L., Rubinstein, M., Cerdán, M. G., Diano, S., Horvath, T. L., Cone, R. D., & Low, M. J. (2001) · Nature · doi:10.1038/35078085 · Cited by 2,356
Self-citationFlint, A., Raben, A., Blundell, J., & Astrup, A. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801083 · Cited by 2,238
The mesolimbic dopamine reward circuit in depression
Nestler, E. J., & Carlezon, W. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.018 · Cited by 2,059
Changes in Energy Expenditure Resulting from Altered Body Weight
Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321001 · Cited by 2,012
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Wang, G.-J., Volkow, N. D., Logan, J., Pappas, N. R., Wong, C. T., Zhu, W., Netusll, N., & Fowler, J. S. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03643-6 · Cited by 1,864
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Anatomy and regulation of the central melanocortin system
Cone, R. D. (2005) · Nature Neuroscience · doi:10.1038/nn1455 · Cited by 1,583
The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review
Klok, M. D., Jakobsdottir, S., & Drent, M. L. (2007) · Obesity Reviews · doi:10.1111/j.1467-789x.2006.00270.x · Cited by 1,442
Saper, C. B., Chou, T. C., & Elmquist, J. K. (2002) · Neuron · doi:10.1016/s0896-6273(02)00969-8 · Cited by 1,120
How can drug addiction help us understand obesity?
Volkow, N. D., & Wise, R. A. (2005) · Nature Neuroscience · doi:10.1038/nn1452 · Cited by 1,089 · cited 1×
“Furthermore, the reward system can undergo neuro-adaptations in response to chronic exposure to rewarding stimuli and it appears that similar changes occur in obesity [72,73].”
BackgroundGadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064
Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947 · cited 1×
“Furthermore, weight regain after lifestyle intervention or cessation of obesity medications is common [17,19,163] and patients who stop taking obesity medications will likely experience at least some weight regain without further intervention.”
BackgroundKelley, A. E. (2004) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2003.11.015 · Cited by 942
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911 · cited 1×
“Furthermore, weight regain after lifestyle intervention or cessation of obesity medications is common [17,19,163] and patients who stop taking obesity medications will likely experience at least some weight regain without further intervention.”
BackgroundLeptin Receptor Signaling in Midbrain Dopamine Neurons Regulates Feeding
Hommel, J. D., Trinko, R., Sears, R. M., Georgescu, D., Liu, Z.-W., Gao, X.-B., Thurmon, J. J., Marinelli, M., & DiLeone, R. J. (2006) · Neuron · doi:10.1016/j.neuron.2006.08.023 · Cited by 902
Wise, R. A. (2002) · Neuron · doi:10.1016/s0896-6273(02)00965-0 · Cited by 881 · cited 1×
“The reward system plays a central role in regulation of eating behavior by mediating the rewarding effects of pleasurable stimuli (food, sex and drugs of abuse) and governs reward-directed behavior [26,39,60,62,63].”
BackgroundLong-term Drug Treatment for Obesity: A Systematic and Clinical Review
Yanovski, S. Z., & Yanovski, J. A. (2014) · JAMA · doi:10.1001/jama.2013.281361 · Cited by 876
Broberger, C., Johansen, J., Johansson, C., Schalling, M., & Hökfelt, T. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.15043 · Cited by 798
Apovian, C. M., Aronne, L., Rubino, D., Still, C., Wyatt, H., Burns, C., Kim, D., Dunayevich, E., & for the COR‐II Study Group (2013) · Obesity · doi:10.1002/oby.20309 · Cited by 720
Allison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711
Leptin Regulates Striatal Regions and Human Eating Behavior
Farooqi, I. S., Bullmore, E., Keogh, J., Gillard, J., O'Rahilly, S., & Fletcher, P. C. (2007) · Science · doi:10.1126/science.1144599 · Cited by 622
Studies on the Physiological Functions of the Melanocortin System
Cone, R. D. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0034 · Cited by 615 · cited 1×
“The endogenous opioid, -endorphin, is produced from the OMC precursor peptide and is released from POMC cells along ith -MSH [53,54].”
BackgroundWadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Perri, M. G., Pi‐Sunyer, F. X., Rock, C. L., Erickson, J. S., et al. (2011) · Obesity · doi:10.1038/oby.2010.147 · Cited by 558
Diet-Induced Obesity Causes Severe but Reversible Leptin Resistance in Arcuate Melanocortin Neurons
Enriori, P. J., Evans, A. E., Sinnayah, P., Jobst, E. E., Tonelli-Lemos, L., Billes, S. K., Glavas, M. M., Grayson, B. E., Perello, M., Nillni, E. A., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.02.004 · Cited by 552
Self-citationWang, G.-J., Volkow, N. D., Thanos, P. K., & Fowler, J. S. (2004) · Journal of Addictive Diseases · doi:10.1300/j069v23n03_04 · Cited by 502
Hollander, P., Gupta, A. K., Plodkowski, R., Greenway, F., Bays, H., Burns, C., Klassen, P., Fujioka, K., & for the COR-Diabetes Study Group (2013) · Diabetes Care · doi:10.2337/dc13-0234 · Cited by 501
Figlewicz, D. P., Evans, S. B., Murphy, J., Hoen, M., & Baskin, D. G. (2003) · Brain Research · doi:10.1016/s0006-8993(02)04087-8 · Cited by 482
Rössner, S., Sjöström, L., Noack, R., Meinders, A. E., Noseda, G., & Study, O. B. O. T. E. O. O. (2000) · Obesity Research · doi:10.1038/oby.2000.8 · Cited by 476
Bupropion SR Enhances Weight Loss: A 48‐Week Double‐Blind, Placebo‐ Controlled Trial
Anderson, J. W., Greenway, F. L., Fujioka, K., Gadde, K. M., McKenney, J., & O'Neil, P. M. (2002) · Obesity Research · doi:10.1038/oby.2002.86 · Cited by 315
The role of dopamine in motivation for food in humans: implications for obesity
Wang, G.-J., Volkow, N. D., & Fowler, J. S. (2002) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.6.5.601 · Cited by 285 · cited 1×
“Considering the broad availability of aggressively marketed, highly palatable food in developed countries, obesity drugs that reduce hedonic feeding behavior may be especially helpful [38,39].”
BackgroundWang, G.-J., Volkow, N. D., Telang, F., Jayne, M., Ma, Y., Pradhan, K., Zhu, W., Wong, C. T., Thanos, P. K., Geliebter, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807423106 · Cited by 242
Bupropion SR vs. Placebo for Weight Loss in Obese Patients with Depressive Symptoms
Jain, A. K., Kaplan, R. A., Gadde, K. M., Wadden, T. A., Allison, D. B., Brewer, E. R., Leadbetter, R. A., Richard, N., Haight, B., Jamerson, B. D., et al. (2002) · Obesity Research · doi:10.1038/oby.2002.142 · Cited by 205
Comparison of Combined Bupropion and Naltrexone Therapy for Obesity with Monotherapy and Placebo
Greenway, F. L., Dunayevich, E., Tollefson, G., Erickson, J., Guttadauria, M., Fujioka, K., Cowley, M. A., & for the NB-201 Study Group (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1350 · Cited by 179 · cited 2×
“In the larger dose-ranging study that led to Phase 3 dose selection, NB-treated subjects had more than twice as much weight loss as those in the bupropion monotherapy group [116].”
BackgroundSelf-citationEffects of overfeeding on the neuronal response to visual food cues
Cornier, M.-A., Von Kaenel, S. S., Bessesen, D. H., & Tregellas, J. R. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.4.965 · Cited by 160
Individual differences in the neurophysiology of reward and the obesity epidemic
Small, D. M. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.71 · Cited by 144 · cited 1×
“The availability of highly palatable food increases reward-based or hedonic feeding in humans and animals [69] and individual differences in the neurophysiology of the reward system have been identified that may explain why certain individuals are at greater risk for weight gain [70,71].”
BackgroundBehavior therapy for obesity: where are we now?
Sarwer, D. B., von Sydow Green, A., Vetter, M. L., & Wadden, T. A. (2009) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32832f5a79 · Cited by 120
Shin, A. C., Pistell, P. J., Phifer, C. B., & Berthoud, H. R. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.07.017 · Cited by 109
Use of prescription antiobesity drugs in the United States.
Hampp, C., Kang, E. M., & Borders‐Hemphill, V. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1342 · Cited by 103
Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity
Smith, S. R., Fujioka, K., Gupta, A. K., Billes, S. K., Burns, C., Kim, D., Dunayevich, E., & Greenway, F. L. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12095 · Cited by 55
Self-citation
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Contemporary medical, device, and surgical therapies for obesity in adults
Perdomo, C. M., Cohen, R. V., Sumithran, P., Clément, K., & Frühbeck, G. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02403-5 · Cited by 738
Food cue reactivity and craving predict eating and weight gain: A meta-analytic review
Boswell, R. G., & Kober, H. (2016) · Obesity Reviews · doi:10.1111/obr.12354 · Cited by 703
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., & Mantzoros, C. S. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101882 · Cited by 462
Physiological adaptations to weight loss and factors favouring weight regain
Greenway, F. L. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.59 · Cited by 431
“The opioid antagonist naltrexone and atypical antidepressant bupropion, which inhibits reuptake of dopamine, may influence food intake and body weight via the reward system.(66) Subjective appetite is accessed by measuring desire to eat, hunger and prospective food consumption 67 using a Visual Analogue Scale (VAS).”
Method
Metadata
- Authors
- Billes, S. K., Sinnayah, P., & Cowley, M. A.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2014-06
- Volume
- 84
- Pages
- 1-11
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W2094384568
- Cited by
- 242
- References
- 45
- FWCI
- 10.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.